Lymph node identification following neoadjuvant therapy in rectal cancer: A stage-stratified analysis using the surveillance, epidemiology, and end results (SEER)-medicare database

Brett L. Ecker, Emily C. Paulson, Jashodeep Datta, Nimalan Jeganathan, Cary Aarons, Rachel R. Kelz, Najjia N. Mahmoud

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and Objectives Neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma reduces lymph node (LN) identification following surgical resection. We sought to evaluate the relationship between LN identification following nCRT and disease-specific survival (DSS), stratified by pathologic stage. Methods The SEER-Medicare database (2000-2009) was queried for 1,216 pathologic stage I-III rectal cancer patients who underwent nCRT followed by curative-intent resection. Cox regressions evaluated the association between pathologic stage and DSS for LN cut-points from ≥2 up to ≥12 LNs. Results Extent of LN identification did not influence DSS in ypStage I or ypStage III disease; in particular, the 12 LN cut-point was not associated with DSS for ypStage I (HR 1.29, P = 0.51) or ypStage III (HR 1.08, P = 0.42) patients. In ypStage II patients, actuarial survival improved continually with increasing lymph node identification up to ≥12 LNs. The 5 LN cut-point was associated with the greatest reduction of risk of cancer death (HR 0.56, P = 0.006), with decreasing magnitudes of survival benefit associated with nodal counts beyond 5 LN. The 12 LN cut-point was not associated with DSS in ypStage II patients (HR 0.67, P = 0.07). Conclusion The association between DSS and LN identification is a dynamic outcome that varies by pathologic stage, with unique prognostic significance for ypStage II patients. J. Surg. Oncol. 2015; 112:415-420.

Original languageEnglish (US)
Pages (from-to)415-420
Number of pages6
JournalJournal of Surgical Oncology
Volume112
Issue number4
DOIs
StatePublished - Sep 1 2015

Fingerprint

Neoadjuvant Therapy
Rectal Neoplasms
Medicare
Epidemiology
Lymph Nodes
Databases
Survival
Risk Reduction Behavior
Adenocarcinoma

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Ecker, Brett L. ; Paulson, Emily C. ; Datta, Jashodeep ; Jeganathan, Nimalan ; Aarons, Cary ; Kelz, Rachel R. ; Mahmoud, Najjia N. / Lymph node identification following neoadjuvant therapy in rectal cancer : A stage-stratified analysis using the surveillance, epidemiology, and end results (SEER)-medicare database. In: Journal of Surgical Oncology. 2015 ; Vol. 112, No. 4. pp. 415-420.
@article{d2ba5bc1637f412499620a671df78da8,
title = "Lymph node identification following neoadjuvant therapy in rectal cancer: A stage-stratified analysis using the surveillance, epidemiology, and end results (SEER)-medicare database",
abstract = "Background and Objectives Neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma reduces lymph node (LN) identification following surgical resection. We sought to evaluate the relationship between LN identification following nCRT and disease-specific survival (DSS), stratified by pathologic stage. Methods The SEER-Medicare database (2000-2009) was queried for 1,216 pathologic stage I-III rectal cancer patients who underwent nCRT followed by curative-intent resection. Cox regressions evaluated the association between pathologic stage and DSS for LN cut-points from ≥2 up to ≥12 LNs. Results Extent of LN identification did not influence DSS in ypStage I or ypStage III disease; in particular, the 12 LN cut-point was not associated with DSS for ypStage I (HR 1.29, P = 0.51) or ypStage III (HR 1.08, P = 0.42) patients. In ypStage II patients, actuarial survival improved continually with increasing lymph node identification up to ≥12 LNs. The 5 LN cut-point was associated with the greatest reduction of risk of cancer death (HR 0.56, P = 0.006), with decreasing magnitudes of survival benefit associated with nodal counts beyond 5 LN. The 12 LN cut-point was not associated with DSS in ypStage II patients (HR 0.67, P = 0.07). Conclusion The association between DSS and LN identification is a dynamic outcome that varies by pathologic stage, with unique prognostic significance for ypStage II patients. J. Surg. Oncol. 2015; 112:415-420.",
author = "Ecker, {Brett L.} and Paulson, {Emily C.} and Jashodeep Datta and Nimalan Jeganathan and Cary Aarons and Kelz, {Rachel R.} and Mahmoud, {Najjia N.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/jso.23991",
language = "English (US)",
volume = "112",
pages = "415--420",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Lymph node identification following neoadjuvant therapy in rectal cancer : A stage-stratified analysis using the surveillance, epidemiology, and end results (SEER)-medicare database. / Ecker, Brett L.; Paulson, Emily C.; Datta, Jashodeep; Jeganathan, Nimalan; Aarons, Cary; Kelz, Rachel R.; Mahmoud, Najjia N.

In: Journal of Surgical Oncology, Vol. 112, No. 4, 01.09.2015, p. 415-420.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lymph node identification following neoadjuvant therapy in rectal cancer

T2 - A stage-stratified analysis using the surveillance, epidemiology, and end results (SEER)-medicare database

AU - Ecker, Brett L.

AU - Paulson, Emily C.

AU - Datta, Jashodeep

AU - Jeganathan, Nimalan

AU - Aarons, Cary

AU - Kelz, Rachel R.

AU - Mahmoud, Najjia N.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background and Objectives Neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma reduces lymph node (LN) identification following surgical resection. We sought to evaluate the relationship between LN identification following nCRT and disease-specific survival (DSS), stratified by pathologic stage. Methods The SEER-Medicare database (2000-2009) was queried for 1,216 pathologic stage I-III rectal cancer patients who underwent nCRT followed by curative-intent resection. Cox regressions evaluated the association between pathologic stage and DSS for LN cut-points from ≥2 up to ≥12 LNs. Results Extent of LN identification did not influence DSS in ypStage I or ypStage III disease; in particular, the 12 LN cut-point was not associated with DSS for ypStage I (HR 1.29, P = 0.51) or ypStage III (HR 1.08, P = 0.42) patients. In ypStage II patients, actuarial survival improved continually with increasing lymph node identification up to ≥12 LNs. The 5 LN cut-point was associated with the greatest reduction of risk of cancer death (HR 0.56, P = 0.006), with decreasing magnitudes of survival benefit associated with nodal counts beyond 5 LN. The 12 LN cut-point was not associated with DSS in ypStage II patients (HR 0.67, P = 0.07). Conclusion The association between DSS and LN identification is a dynamic outcome that varies by pathologic stage, with unique prognostic significance for ypStage II patients. J. Surg. Oncol. 2015; 112:415-420.

AB - Background and Objectives Neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma reduces lymph node (LN) identification following surgical resection. We sought to evaluate the relationship between LN identification following nCRT and disease-specific survival (DSS), stratified by pathologic stage. Methods The SEER-Medicare database (2000-2009) was queried for 1,216 pathologic stage I-III rectal cancer patients who underwent nCRT followed by curative-intent resection. Cox regressions evaluated the association between pathologic stage and DSS for LN cut-points from ≥2 up to ≥12 LNs. Results Extent of LN identification did not influence DSS in ypStage I or ypStage III disease; in particular, the 12 LN cut-point was not associated with DSS for ypStage I (HR 1.29, P = 0.51) or ypStage III (HR 1.08, P = 0.42) patients. In ypStage II patients, actuarial survival improved continually with increasing lymph node identification up to ≥12 LNs. The 5 LN cut-point was associated with the greatest reduction of risk of cancer death (HR 0.56, P = 0.006), with decreasing magnitudes of survival benefit associated with nodal counts beyond 5 LN. The 12 LN cut-point was not associated with DSS in ypStage II patients (HR 0.67, P = 0.07). Conclusion The association between DSS and LN identification is a dynamic outcome that varies by pathologic stage, with unique prognostic significance for ypStage II patients. J. Surg. Oncol. 2015; 112:415-420.

UR - http://www.scopus.com/inward/record.url?scp=84942292930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942292930&partnerID=8YFLogxK

U2 - 10.1002/jso.23991

DO - 10.1002/jso.23991

M3 - Article

C2 - 26250884

AN - SCOPUS:84942292930

VL - 112

SP - 415

EP - 420

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -